Background. The development of atherosclerosis may be enhanced by iron accumulation in macrophages. Hepcidin-25 is a key regulator of iron homeostasis, which downregulates the cellular iron exporter ferroportin. In haemodialysis (HD) patients, hepcidin-25 levels are increased. Therefore, it is conceivable that hepcidin-25 is associated with all-cause mortality and/or fatal and non-fatal cardiovascular (CV) events in this patient group. The aim of the current analysis was to study the relationship between hepcidin-25 and all-cause mortality and both fatal and non-fatal CV events in chronic HD patients.
1.26; P = 0.01], but not after adjustment for all confounders including high-sensitive C-reactive protein (HR 1.02 per 10 nmol/L, 95% CI 0.87-1.20; P = 0.80). At the same time, hepcidin-25 was significantly related to fatal and non-fatal CV events in a fully adjusted model (HR 1.24 per 10 nmol/L, 95% CI 1.05-1.46, P = 0.01). Conclusion. Hepcidin-25 was associated with fatal and nonfatal CV events, even after adjustment for inflammation. Furthermore, inflammation appears to be a significant confounder in the relation between hepcidin-25 and all-cause mortality. These findings suggest that hepcidin-25 might be a novel determinant of CV disease in chronic HD patients.
I N T RO D U C T I O N
Cardiovascular (CV) mortality and morbidity are extremely high in chronic haemodialysis (HD) patients [1] . The pathogenesis of CV disease in patients with end-stage renal disease is complex and various mechanisms have been proposed [2] . Recently, it was suggested that iron accumulation in vascular cells or macrophages in the vascular wall may lead to oxidative stress, eventually resulting in atherosclerosis and endothelial dysfunction [3] . This may be of eminent importance as chronic HD patients are often treated with large amounts of intravenous iron [4] . Indeed, it has been shown that both ferritin levels and cumulative intravenous iron dose were associated with carotid intima-media thickness (cIMT) in chronic HD patients [5] .
In 2001, a peptide with antimicrobial properties was discovered, named hepcidin [6, 7] . The bioactive isoform hepcidin-25 turned out to be a key regulator of iron homeostasis. Hepcidin-25 induces internalization and degradation of ferroportin, which is a cellular iron exporter on enterocytes, macrophages and hepatocytes. The expression of hepcidin is regulated in response to iron administration, erythropoietic demand, hypoxia and inflammatory signals [8, 9] . Hepcidin is produced by the liver and excreted with the urine [10] . In patients with chronic kidney disease (CKD), hepcidin levels are increased, with even higher levels in those on dialysis [11] . Many studies have reported a strong relationship between hepcidin and ferritin in HD patients [11] [12] [13] [14] [15] [16] , whereas the relationship with the (maintenance) dose of erythropoiesis-stimulating agents (ESAs) and ESA resistance is controversial [14, 17] .
Recently, several papers on the relationship between hepcidin and CV disease and atherosclerosis in different patient groups have been published [18] [19] [20] . These data support the hypothesis that hepcidin may be involved in the progression of atherosclerosis, possibly by iron trapping in macrophages in atherosclerotic plaques enhancing oxidative stress. However, it is unknown whether hepcidin is associated with the high rate of mortality and CV disease in HD patients.
The aim of the current analysis was to study whether hepcidin-25 is related to all-cause mortality and/or fatal and nonfatal CV events in a cohort of over 400 chronic HD patients included in the CONvective TRAnsport STudy (CONTRAST).
M AT E R I A L S A N D M E T H O D S
Patients and study design Data from patients enrolled in the CONTRAST study (NCT00205556) were used. The rationale and the design of the CONTRAST study have been described before [21] . In short, prevalent HD patients were recruited from June 2004 until December 2009 and randomized to either continue treatment with low flux HD or switch to treatment with postdilution online haemodiafiltration (HDF), with a follow-up until December 2010. The primary end point of the study was all-cause mortality [22] . CV disease and anaemia management were secondary end points. A total of 714 patients were recruited from 29 dialysis centres. In the design phase of CON-TRAST, a protocol for blood sampling and storage was added, specifically for future studies on newly identified markers that would become potentially relevant and of interest. Hepcidin is an example of such a marker. In 17 of the 29 dialysis centres, in which blood sampling and storage was logistically feasible, predialysis blood samples from participating patients were drawn and stored at −80°C. The selection of centres participating in this sub-study was made prior to enrolment. The present post-hoc analyses were based on a subset of patients from the main study, namely those participants (n = 405) from whom additional blood samples were collected.
Patients were eligible for inclusion in the main study if they were treated with HD for at least 2 months. Exclusion criteria were age below 18 years, treatment with haemo(dia)filtration or high-flux HD in the 6 months prior to randomization, a life expectancy <3 months due to non-renal disease, participation in another clinical intervention trial evaluating CV outcomes and severe incompliance regarding frequency and/or duration of dialysis treatment.
The study was conducted in accordance with the Declaration of Helsinki and was approved by a central medical ethics committee and by all local medical ethics review boards. Written informed consent was obtained from all patients prior to enrolment.
Treatment protocol
Before randomization in the main study, all patients were treated with low-flux polysulfone or polyarylethersulfone dialysers [UF coefficient <20 mL/mmHg/h and surface area 1. Routine patient care and prescription of medication was practiced according to the judgement of the attending nephrologist and based on the Quality of Care Guidelines of the Dutch Federation of Nephrology.
Laboratory protocol
Predialysis blood samples were drawn and routine laboratory assessments were performed in the local hospitals by standard laboratory techniques. Hepcidin-25, soluble transferrin receptor (sTfR) and high-sensitive C-reactive protein (hsCRP) measurements were preformed centrally. For this purpose, predialysis blood samples were centrifuged at 1500 g and 4°C for 10 min and stored at −80°C.
Measurement of serum hepcidin-25 was centrally performed by a validated combination of weak cation exchange (WCX) bead-based hepcidin enrichment followed by time-offlight mass spectrometry (WCX-TOF-MS) [23] . For the quantification of hepcidin-25 in serum, an internal standard (synthetic hepcidin-24, Peptide International Inc., Louisville, KY, USA) was used [24] . Mass-to-charge spectra were generated by using MALDI-TOF-MS (Microflex LT Bruker Daltonics GmbH, Bremen, Germany) with a lower limit of detection of 0.5 nmol/L and an intra-assay coefficient of variation of 2.2% at 3.1 nmol/L, 3.7% at 7.9 nmol/L and 2.3% at 13.4 nmol/L. The inter-assay coefficient of variation was 9.1% at 7.8 nmol/L and 3.9% at 12.9 nmol/L [23] . This method enables the specific measurement of hepcidin-25 and has been described before in CKD and HD patients [11] . sTfR (milligrams per litre) was measured immunonephelometrically on a BN II System (Dade Behring Marburg GmbH, Marburg, Germany). hsCRP (milligram per litre) was measured with a particle-enhanced immunoturbidimetric assay on a RocheHitachi analyser (Roche Diagnostics GmbH, Mannheim, Germany) with a lower quantification limit of 0.1 mg/L and an intra-assay coefficient of variation of 1.9% at the level of 0.57 mg/L and 0.3% at the level of 3.00 mg/L. The inter-assay coefficient of variation of the hsCRP assay was 1.9% at the level of 0.67 mg/L and 1.2% at the level of 3.64 mg/L.
Data Collection
Data on demography, cause of renal failure, history of CV disease, diabetes mellitus, type of vascular access, dialysis vintage and treatment parameters were collected, as well as prescription of medication. Residual renal function (RRF) was defined as a urine production of >100 mL/day. In patients with RRF, the estimated glomerular filtration rate (eGFR) was calculated as the mean of creatinine and urea clearance in a 24-h urine collection, adjusted for body surface area [25] . ESA was prescribed as epoetin α or β (Eprex ® or Neorecormon ® respectively, IU) or darbepoetin α (Aranesp ® , μg) and expressed as a dose per week. To compare the different types of ESA, prescribed dosages were converted to daily defined doses (DDD), using conversion factors as provided by the World Health Organization (WHO) Drug Classification (http://www. whocc.no/atc_ddd_index/). For darbepoetin α (ATC code B03XA02), DDD is 4.5 μg and for epoetin α and β (ATC code B03XA01), DDD is 1000 IU. All patients on iron therapy used iron sucrose (Venofer ® , mg). CV events were reported by the local centres and adjudicated by an independent end point committee. They were defined as death from CV causes (including sudden death and congestive heart failure), non-fatal coronary heart disease, non-fatal stroke, amputation or revascularization interventions, consisting of therapeutic coronary procedures (coronary artery bypass graft, percutaneous transluminal coronary angioplasty and/or stenting), therapeutic carotid procedures (endarterectomy and/or stenting) and vascular interventions ( peripheral bypass surgery, percutaneous transluminal angioplasty and/or stenting, not related to the vascular access for dialysis).
Statistical analysis
Variables were reported as proportions or means ± standard deviation (SD), or medians with 25th-75th percentiles when appropriate. Correlations between biochemical parameters were evaluated with a Spearman correlation test.
The relations between hepcidin-25 and all-cause mortality, as well as hepcidin-25 and fatal or non-fatal CV events, were evaluated by Cox proportional hazard models. First, determinants of all-cause mortality and CV events were identified by entering demographic (age, sex, race, dialysis vintage, diabetes, history of CV disease, smoking status, eGFR), clinical (body mass index, systolic and diastolic blood pressure, treatment time, treatment frequency, dialysis spKt/V urea , dialyser type, prescription of renin-angiotensin system inhibitors, calcium blockers, statins, ESA and iron therapy) and biochemical parameters [haemoglobin, ferritin, transferrin saturation ratio (TSAT), cholesterol, albumin, phosphate, calcium, parathyroid hormone, soluble transferrin receptor and hsCRP] in a Cox proportional hazard model following a backstep elimination procedure using a P-value of 0.20 as a cut-off. Secondly, demographic, clinical and biochemical determinants of hepcidin-25 were identified using a backward multivariate regression analysis [14] .
Finally, the relationship between hepcidin-25 and all-cause mortality as well as hepcidin-25 and CV events were analysed by examining the following Cox proportional hazard models: (i) crude analysis; (ii) adjustment for demographic and clinical determinants related to all-cause mortality or CV events; (iii) additional adjustment for demographic and clinical determinants related to hepcidin-25; (iv) additional adjustment for biochemical parameters: (a) excluding ferritin and hsCRP; (b) after additional adjustment for ferritin; (c) after additional adjustment for hsCRP. The proportional hazard assumption was tested by adding an interaction term (hepcidin-25 × time) to the Cox proportional hazard models. We analysed the first event that occurred after randomization. All models were adjusted for the treatment modality (HD versus HDF) in the main study. Only patients with complete data available were included.
Furthermore, hepcidin-25 was analysed into categories (tertiles). A multivariable Cox proportional hazard model was used to calculate the cumulative event-free survival in patients stratified according to hepcidin-25 tertiles.
In the final models, a double-sided P-value of <0.05 was considered statistically significant. Statistical analyses were performed with PASW software (version 18.0, SPSS inc. Headquarters, Chicago, IL, USA).
R E S U LT S

Baseline characteristics
As can be seen from Table 1 , baseline characteristics for the entire CONTRAST baseline cohort (n = 714; 'Entire cohort') were similar with patients in whom hepcidin and other specific laboratory markers were measured (n = 405; 'Hepcidin cohort'). When the patients with and without hepcidin measurements were compared (data not shown), differences were observed in the use of ESA, the use and dose of iron supplementation, and ferritin and albumin levels (P < 0.001, adjusted for multiple testing).
Mean ± SD age of the study population in the hepcidin cohort was 63.7 ± 13.9 years and 62% was male (Table 1) . Median (interquartile range) level of hepcidin-25 was 13.8 (6.6-22.5). The distribution of hepcidin-25 was positively skewed (Figure 1 ).
Events during follow-up
The median follow-up of patients in the hepcidin cohort was 3.0 years (minimum 0.8, maximum 6.6 years). A total of 158 (39%) patients died from any cause and 131 (32%) patients had a CV event (including death from CV events and 'sudden death'). In the entire cohort, these numbers were 269 (38%) and 228 (32%), respectively. The subsequent paragraphs will focus exclusively on the hepcidin cohort (n = 405).
The cause of death was CV (n = 49), infection (n = 41), cancer (n = 10), stopping further treatment (n = 33), other (n = 16) and unknown (n = 9). The CV deaths comprised of stroke (n = 6), coronary heart disease (n = 5), sudden death (n = 27), congestive heart failure (n = 5) and other causes (n = 6). CV events comprised of stroke (n = 13), coronary heart disease (n = 42), sudden death (n = 19), congestive heart failure (n = 3), lower extremity amputations (n = 13), 36 revascularization procedures and 5 other vascular events. Of note, the first CV event that occurred after randomization was analysed (see Statistical analysis section).
During follow-up, 95 patients received a renal transplant and 7 switched from HD to peritoneal dialysis.
Relationship between hepcidin and all-cause mortality As can be seen from Table 2 , hepcidin-25 was related to allcause mortality in a multivariate Cox regression model after adjustment for various demographic, clinical and biochemical determinants of mortality and hepcidin-25 (model 1-4a). However, after adjustment for ferritin and hsCRP, the relationship between hepcidin-25 and mortality was no longer present (HR 1.02 [95% CI 0.87-1.20], P = 0.80). Ferritin and hsCRP were weakly correlated (r = 0.15; P = 0.004), and both parameters were strongly associated with hepcidin-25 levels in multivariate regression analysis (P < 0.001 for both parameters).
Relationship between hepcidin and fatal and non-fatal CV events As can be seen from Table 3 , hepcidin-25 was related to fatal and non-fatal CV events in all Cox proportional hazard models tested (Models 1-4c) . The relation was somewhat weaker, albeit still significant, after adjustment for hsCRP (HR 1.24 [95% CI 1.05-1.46], P = 0.01).
In our study population, maintenance weight-adjusted ESA dose was neither identified as an independent determinant of CV events (P = 0.31), nor of hepcidin-25 (P = 0.46). Therefore, as could be expected, additional adjustment for ESA dose in the Cox proportional hazard analysis did not change the relation between hepcidin-25 and CV events (HR 1.24 [95% CI 1.05-1.47], P = 0.01).
The analysis with hepcidin-25 in tertiles showed that especially patients in the highest hepcidin tertile manifested an increased risk for CV disease (Figure 2 ). The adjusted hazard ratio for patients in the 3rd tertile versus those in the 1st tertile was 1.60 (95% CI 1.22-1.80; P = 0.007) and versus those in the 2nd tertile 1.54 (95% CI 1.19-1.73; P = 0.007). Drop-outs because of renal transplantation and switch to peritoneal dialysis were equally distributed across the tertiles.
For both the analysis on all-cause mortality and on CV events, the interaction term (hepcidin-25 × time) was statistically significant (P < 0.01). This implicates that the proportional hazard assumption was violated and, as can be seen in Figure 2 , the differences in risk between the strata of hepcidin-25 increased with follow-up.
D I S C U S S I O N
In the current study, it was shown that hepcidin-25 was significantly associated with fatal and non-fatal CV events in chronic HD patients, after adjustment for several demographic, clinical and biochemical determinants. Especially patients with the highest hepcidin-25 levels were at risk. The association between hepcidin and all-cause mortality disappeared after adjustment for hsCRP and ferritin.
Our results may implicate that hepcidin plays a role in the pathophysiology of atherosclerosis and CV disease, as has been suggested before [3] . In older epidemiological studies, the relationship between iron stores and atherosclerotic disease in the general population was controversial [26] [27] [28] . Recently, however, the role of iron in relation to CV disease has gained renewed attention [29] . It was hypothesized that hepcidin promotes the progression of atherosclerotic plaques by slowing or preventing the mobilization of iron from macrophages [30] . This 'atherosclerotic iron trapping' in macrophages subsequently results in enhanced oxidative stress and increased atherogenicity.
Several recent ( pre-)clinical studies support this hypothesis. It has been shown that in patients with extensive atherosclerotic plaques, atherosclerotic iron content was associated with pro-oxidant activity within the plaque [31] , and ironladen macrophages exhibited pro-atherogenic activity by oxidization of low-density lipoproteins (LDLs) [32] . In an experimental mouse model, suppression of hepcidin resulted in a reduced iron content of macrophages, and subsequently in an increased efflux capacity of cholesterol, which was associated with reduced foam cell formation and atherosclerosis [33] . Moreover, in human monocytes derived from atherosclerotic plaques, intracellular iron content was increased in the presence of hepcidin, resulting in enhanced reactive oxygen substances, which prevented cholesterol efflux from these cells [34] . In patients with non-alcoholic fatty liver disease, hyperferritinaemia was independently associated with vascular damage (as reflected by cIMT), only in patients with normal haemochromatosis genotypes, which was associated with upregulation of hepcidin [20] . In a similar patient group, monocyte chemoattractant protein-1, a chemokine that plays a crucial role in both the initiation and progression of atherosclerosis, was correlated with hepcidin-25 and an independent predictor for the presence of atherosclerotic plaques [19] . Finally, in 168 chronic HD patients, [44] . Conversion factors for units: haemoglobin in g/dL to mmol/L, ×0.62; cholesterol in mg/dL to mmol/L, ×0.026; albumin in g/dL to g/L, ×10; no conversion necessary for ferritin in ng/mL to µg/L. 
O R I G I N A L A R T I C L E
H e p c i d i n a n d c a r d i o v a s c u l a r e v e n t s i n h a e m o d i a l y s i s p a t i e n t s hepcidin-25 was independently associated with arterial stiffness measured by brachial-ankle pulse wave velocity measurements [18] .
Apart from iron accumulation, other pathogenic mechanisms may be involved in the effect of hepcidin-25 on atherosclerotic plaques. As adjustment for hsCRP attenuated the relationship between hepcidin-25 and all-cause mortality, our findings suggest that the mechanism involved runs through inflammation. In this respect, it is interesting to note that, previously, inflammation has been associated with both CV disease [35] and hepcidin levels [13, 14] . Furthermore, it has been hypothesized that oxidative stress in atherosclerotic plaques ultimately leads to death of the iron-laden macrophages and release of its cellular contents, which enhances The changes in hazard ratios of the different covariates during the modelling process are available in Table B inflammatory stimuli resulting in additional upregulation of hepcidin synthesis [30] . As mentioned earlier, the absent relationship between hepcidin-25 and all-cause mortality may be caused by the overriding effect of inflammation. Another explanation could be that hepcidin appears to be specifically involved in the pathogenesis of CV disease, and fatal CV events accounted only for 31% of the total mortality in our study population. Furthermore, 26% of all cases of death were due to an infection. As hepcidin behaves as an acute phase reactant, increasing during inflammation, this may explain the confounding effect of the inflammation marker hsCRP on the relationship between hepcidin-25 and mortality.
In CKD patients, vascular intima and media calcification are important causes of CV disease [2] . In the presented Cox regression models, no adjustments for calcification markers as calcium, phosphate and parathyroid hormone were made, as these markers were not associated with mortality, CV events or hepcidin. However, additional adjustment for these parameters did not change our results (data not shown). Whether other non-classical markers such as vitamin D, fetuin A [36] and fibroblast growth factor 23 [37] would have modified our results is a topic for further research.
It is well known that ESA resistance is associated with an adverse outcome [38, 39] . Furthermore, it has been shown that ESA dose and ESA resistance are associated with hepcidin levels measured with a competitive radio-immunoassay [17] . In our cohort, we did not observe a relationship between hepcidin and weight-adjusted ESA dose or ESA resistance in the backward multivariate regression analysis. Moreover, we have shown that additional adjustment for an ESA dose in the final model did not change the results.
Our findings might have implications regarding clinical decisions on iron supplementation, as our data challenge the safety of unrestricted administration of intravenous iron in dialysis patients. The Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) trial showed that haemoglobin levels increased in patients with high ferritin levels (and low TSAT) on stable ESA therapy [40] , although the study was not designed to draw any conclusions on safety aspects. Thus far, no prospective trials on the long-term safety of intravenous iron supplementation, especially with respect to CV events, have been published [41, 42] . Of note, definite conclusions on the safety of iron administration with respect to CV events and mortality cannot be drawn from our study. However, our results might implicate that iron supplementation in HD patients should be administered cautiously, especially in patients with high hepcidin levels and/or an inflammatory state.
As far as we know, we are the first to show an association between hepcidin and clinical events in chronic HD patients. A potential limitation of our study may be the fact that we measured hepcidin levels only at baseline. It has been shown that there is a significant intra-individual variability in hepcidin which is likely dependent on fluctuations in inflammation [43] . However, we believe that hepcidin concentrations will not vary significantly on a population level. Furthermore, there might be a selection bias as significant differences in some clinically relevant parameters between patients with and without hepcidin measurements at baseline were present, within the total CON-TRAST patient cohort. The effect of these differences on the study outcome, however, is unclear, since it is unknown whether the relations under study (i.e. hepcidine associated with mortality or CV events) differ between patients from whom samples were available or not. As a result, we can neither confirm nor exclude a potential sampling bias.
Finally, our study may be limited by the fact that the hazard ratios in the Cox proportional hazard models may be slightly overestimated due to the high number of covariates added in these models.
The strength of our study is the accurate and prospective data collection and the adjudication of clinical events by an independent event committee. Furthermore, hepcidin-25 measurements were centrally performed with a precise and validated method.
In conclusion, in this study in 405 prevalent HD patients, we observed an association between hepcidin-25 and fatal and non-fatal CV events. Our findings could be explained by excessive iron deposition in macrophages, which enhances oxidative stress in atherosclerotic plaques. Furthermore, inflammation appears to be a significant confounder. Still, the exact underlying mechanism of the described association and the possible causality of our findings remain to be established in prospective studies.
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